Literature DB >> 28961849

'Thursday's child has far to go'-interpreting subgroups and the STAMPEDE trial.

M R Spears1, N D James2, M R Sydes3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28961849      PMCID： PMC5777583          DOI： 10.1093/annonc/mdx410

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  11 in total

1.  Forest plots: trying to see the wood and the trees.

Authors:  S Lewis; M Clarke
Journal:  BMJ       Date:  2001-06-16

2.  A consumer's guide to subgroup analyses.

Authors:  A D Oxman; G H Guyatt
Journal:  Ann Intern Med       Date:  1992-01-01       Impact factor: 25.391

3.  Multiplicity in randomised trials II: subgroup and interim analyses.

Authors:  Kenneth F Schulz; David A Grimes
Journal:  Lancet       Date:  2005 May 7-13       Impact factor: 79.321

Review 4.  Subgroup analyses: how to avoid being misled.

Authors:  John Fletcher
Journal:  BMJ       Date:  2007-07-14

5.  Statistical problems in the reporting of clinical trials. A survey of three medical journals.

Authors:  S J Pocock; M D Hughes; R J Lee
Journal:  N Engl J Med       Date:  1987-08-13       Impact factor: 91.245

6.  The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials.

Authors:  J A Freiman; T C Chalmers; H Smith; R R Kuebler
Journal:  N Engl J Med       Date:  1978-09-28       Impact factor: 91.245

7.  Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials.

Authors:  S Yusuf; J Wittes; J Probstfield; H A Tyroler
Journal:  JAMA       Date:  1991-07-03       Impact factor: 56.272

8.  The problem of subgroup analyses: an example from a trial on ruptured intracranial aneurysms.

Authors:  O Naggara; J Raymond; F Guilbert; D G Altman
Journal:  AJNR Am J Neuroradiol       Date:  2011-03-24       Impact factor: 3.825

9.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Authors:  Nicholas D James; Matthew R Sydes; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Melissa R Spears; Alastair W S Ritchie; Christopher C Parker; J Martin Russell; Gerhardt Attard; Johann de Bono; William Cross; Rob J Jones; George Thalmann; Claire Amos; David Matheson; Robin Millman; Mymoona Alzouebi; Sharon Beesley; Alison J Birtle; Susannah Brock; Richard Cathomas; Prabir Chakraborti; Simon Chowdhury; Audrey Cook; Tony Elliott; Joanna Gale; Stephanie Gibbs; John D Graham; John Hetherington; Robert Hughes; Robert Laing; Fiona McKinna; Duncan B McLaren; Joe M O'Sullivan; Omi Parikh; Clive Peedell; Andrew Protheroe; Angus J Robinson; Narayanan Srihari; Rajaguru Srinivasan; John Staffurth; Santhanam Sundar; Shaun Tolan; David Tsang; John Wagstaff; Mahesh K B Parmar
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321

10.  Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.

Authors:  Malcolm D Mason; Noel W Clarke; Nicholas D James; David P Dearnaley; Melissa R Spears; Alastair W S Ritchie; Gerhardt Attard; William Cross; Rob J Jones; Christopher C Parker; J Martin Russell; George N Thalmann; Francesca Schiavone; Estelle Cassoly; David Matheson; Robin Millman; Cyrill A Rentsch; Jim Barber; Clare Gilson; Azman Ibrahim; John Logue; Anna Lydon; Ashok D Nikapota; Joe M O'Sullivan; Emilio Porfiri; Andrew Protheroe; Narayanan Nair Srihari; David Tsang; John Wagstaff; Jan Wallace; Catherine Walmsley; Mahesh K B Parmar; Matthew R Sydes
Journal:  J Clin Oncol       Date:  2017-03-13       Impact factor: 44.544
View more
  4 in total

1.  Missing the trees for the forest: most subgroup analyses using forest plots at the ASCO annual meeting are inconclusive.

Authors:  Andrew W Hahn; Nazli Dizman; Pavlos Msaouel
Journal:  Ther Adv Med Oncol       Date:  2022-06-01       Impact factor: 5.485

2.  Lack of Evidence Does Not Equal Lack of Benefit: Neoadjuvant Chemotherapy and Trimodality Therapy in Selected Patients with Muscle-Invasive Bladder Cancer : In response to: Dirk Böhmer and Arne Grün. Lacking Evidence to Recommend Neoadjuvant Chemotherapy and Definitive Radiotherapy in Muscle-Invasive Bladder Cancer.

Authors:  Di Maria Jiang; Peter Chung; Girish S Kulkarni; Nick D James; Srikala S Sridhar
Journal:  Curr Oncol Rep       Date:  2021-03-03       Impact factor: 5.075

Review 3.  Contemporary role of postoperative radiotherapy for prostate cancer.

Authors:  Alan Dal Pra; Matthew C Abramowitz; Radka Stoyanova; Alan Pollack
Journal:  Transl Androl Urol       Date:  2018-06

Review 4.  A Causal Framework for Making Individualized Treatment Decisions in Oncology.

Authors:  Pavlos Msaouel; Juhee Lee; Jose A Karam; Peter F Thall
Journal:  Cancers (Basel)       Date:  2022-08-14       Impact factor: 6.575
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.